Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.58 |
| ▸ | TYMS | P04818 | 14/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23229338 | 0.84 | PARP1 (0.58) | PARP1TYMSALDH1A1TNKS2BMPR1B | |
| SCHEMBL16306348 | 0.83 | PARP1 (0.61) | PARP1TYMSALDH1A1TNKS2 | |
| SCHEMBL19992101 | 0.83 | PARP1 (0.66) | PARP1TYMSALDH1A1TNKS2BMPR1B | |
| SCHEMBL19992061 | 0.81 | PARP1 (0.62) | PARP1TYMSALDH1A1TNKS2BMPR1B | |
| SCHEMBL19992076 | 0.77 | PARP1 (0.66) | PARP1TYMSALDH1A1TNKS2BMPR1B | |
| SCHEMBL19992074 | 0.74 | PARP1 (0.62) | PARP1TYMSALDH1A1TNKS2BMPR1B | |
| SCHEMBL12169915 | 0.73 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL30704850 | 0.73 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL9518147 | 0.73 | PARP1 (0.64) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL6651474 | 0.72 | TYMS (1.00) | PARP1TYMSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | PARP1 4212/4885TYMS 4532/4885ALDH1A1 3565/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | PARP1 4212/4885TYMS 4532/4885ALDH1A1 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.